Free Submission Public Relations &
Deutsch English

Global Pharmaceutical & Biotechnology Outlook 2013: India Pharma

India pharmaceuticals market: 18% growth between 2012-2016

Print article Print article
2014-03-14 09:20:02 - Global Pharmaceutical & Biotechnology Outlook 2013: India Pharma - a new market research report on

India pharma rode on the wave of bunched up patent expiries in the US with many Para IV launches in 2012. In addition, it also benefited from the continuing high teen growth of Indian pharma market. With patent expiries in the US dwindling from $30b in 2012 to $10b in 2013 (small molecules), Indian generic companies will now need to focus on complex generics that offer sustainability of earnings.

Locally acting drugs and targeted drug delivery products make up for the bulk of complex formulation generics. We have analyzed this space and have provided a fairly comprehensive list of products falling under these categories indicating that topical drugs remains the most near term opportunity for generics. Inhalers offer the most lucrative



opportunity, though not before 2016.

Our growth outlook on Indian market continues to remain optimistic with 15-18% growth. This is based on the silent reforms in India that started with implementation of a strict GMP (Good Manufacturing Practices) in 2005, continued with implementation of GLP (Good Laboratories Practices) in 2011 and now the bar coding norms at primary and secondary levels. All these continue to put pressure on the very small manufacturer ultimately leading to industry consolidation - something that augurs well for world´s most fragmented pharma market. We do not see any negative impact due to the newly announced National Pharma Pricing Policy (NPPP) due to its emphasis on market price based pricing policy.

Our top pick remains Sun Pharma as it remains the best positioned to tide over the patent cliff with its latest acquisitions, DUSA and URL Pharma. A strong balance sheet further allows it to acquire more such high value targets. We also recommend Natco Pharma for its focus on complex generics like Copaxone, Revlimid and Tamiflu. Besides this, its domestic market strategy targeted at gaining Compulsory License on high value oncology products too remains lucrative.

Key Topics Covered

Complex Formulations - Scope and Opportunity in US market
Liposomal Drugs: Opportunities for Generic Companies
Colon Targeted Drugs: Opportunities for Generic Companies
Transdermal Drugs: Opportunities for Generic Companies
Topical Dermatological Drugs: Opportunities for Generic Companies
Inhalers: Opportunities for Generic Companies
Reforms and Consolidation Continues in Domestic Market
New Pharma Pricing Policy - Neutral to Positive for the Industry
IPCA: Momentum Continues
Natco: Entering the Big League Through Multi Pronged Strategy
Sun Pharma: Balance Sheet Leveraging at Play
Aurobindo: Still Not Out of the Woods
Dishman: Management Accepts The Limitations of Pure Play Crams
Biocon: Expenses More Visible than Growth Drivers
Cadila Healthcare: In a Phase of Consolidation
Cipla: Weakness in Regulated Markets Persists

Click for report details: ..

Browse all Healthcare and Medical Market Research Reports ..

Browse all Healthcare and Medical Company Profile Reports ..

Browse all Latest Market Research Reports ..

About Us is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles,’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.

Mike King
Phone: London: +44 (0) 203 086 8600

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News


Terms & Conditions | Privacy | About us | Contact